New hope for Hard-to-Treat prostate cancer? early trial underway

NCT ID NCT04428788

Completed Disease control Sponsor: Celgene Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested a new drug called CC-94676 in 131 men with metastatic castration-resistant prostate cancer, a type that has stopped responding to standard hormone therapy. The main goal was to check safety and find the right dose, while also looking for signs that the drug might shrink tumors or lower PSA levels. Results will help decide if further studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CC-94676 (also known as BMS-986365)
What this could lead to: If this drug proves safe and effective, it could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early phase 1 trial focused on safety and dosing, so it is too soon to know if CC-94676 will work. Side effects are unknown, and many drugs fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma neoplasm prostate cancer prostate neoplasm Prostatic Neoplasms, Castration-Resistant

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATIC NEOPLASMS

Contacts and locations

Locations

Local Institution - 101

San Antonio, Texas, 78229, United States
Local Institution - 102

Grand Rapids, Michigan, 49546, United States
Local Institution - 103

Sarasota, Florida, 34232, United States
Local Institution - 104

Boston, Massachusetts, 02215, United States
Local Institution - 105

New York, New York, 10065, United States
Local Institution - 106

Durham, North Carolina, 27710, United States
Local Institution - 107

Dallas, Texas, 75235, United States
Local Institution - 108

Baltimore, Maryland, 21287, United States
Local Institution - 109

New York, New York, 10032, United States
Local Institution - 111

Madison, Wisconsin, 53792, United States
Local Institution - 112

New York, New York, 10029, United States
Local Institution - 113

Philadelphia, Pennsylvania, 19104, United States
Local Institution - 115

Seattle, Washington, 98109, United States
Local Institution - 116

Stanford, California, 94305-5826, United States
Local Institution - 117

Ann Arbor, Michigan, 48109, United States
Local Institution - 119

Houston, Texas, 77030, United States
Local Institution - 120

Allentown, Pennsylvania, 18103, United States
Local Institution - 121

Thomasville, Georgia, 31792, United States
Local Institution - 122

Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.